AstraZeneca and Bristol Myers Squibb Discussing Potential $400B Pharma Merger

The pharmaceutical industry may soon witness its largest merger in history. AstraZeneca (LSE: AZN) and Bristol Myers Squibb (NYSE: BMY) are reportedly in preliminary talks about merging into a single company valued at nearly $400 billion. This news was initially reported by the Financial Times and later confirmed by sources to Reuters and Bloomberg.

The proposed merger would establish a significant presence in the global oncology market. AstraZeneca’s cancer treatments generated approximately $25 billion in 2025 sales — nearly half of the company’s total revenue. Meanwhile, oncology drugs accounted for over 40% of Bristol Myers’ sales in the first half of 2026. Despite the overlap in oncology, cardiovascular disease, and immunology, analysts observe that their pipelines are largely complementary. AstraZeneca leads in solid tumors, while Bristol Myers specializes in blood cancers and cell therapies.

The markets responded dramatically to this news. AstraZeneca shares dipped by as much as 7.8% in London trading, while Bristol Myers saw an increase of up to 3.8% in premarket trading. Analysts have described this move as a “surprise”, given AstraZeneca’s top-tier pipeline. Antitrust experts caution that the deal would likely face rigorous regulatory scrutiny from the U.S. Federal Trade Commission. The companies have not confirmed whether the merger will proceed, and sources suggest it could still be delayed or fall apart entirely.

Source: CNBC — AstraZeneca in Talks with Bristol Myers Squibb on $400 Billion Megadeal